Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

Yeong “Christopher” Choi, PhD, MBA, discusses the importance of developing biomedical technologies for hematologic malignancies and other diseases.

Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 robot-assisted minimally invasive esophagectomies from 2020-2024.

Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.

Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.

Roswell Park-led study takes a significant step toward relief without opioid.

Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

Roswell Park Comprehensive Cancer Center has been recognized as a Center of Excellence for both adult and pediatric cancer treatment by Optum.

Roswell Park Comprehensive Cancer Center’s Intensive Care Unit has earned the Beacon Award for Excellence from the AACN.

Renier Brentjens, MD, PhD, details 3 reasons it’s challenging to make CAR T-cell therapies applicable for solid tumors and ways to overcome the obstacles.

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.

5 WNY organizations received funding to advance cancer prevention, early detection, and patient support from Roswell Park Comprehensive Cancer Center.

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

Data published in Oncogene suggest that the mitochondrial unfolded protein response could be an Achilles’ heel for neuroendocrine prostate cancer.

A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.

Sessions at San Antonio Breast Cancer Symposium address exercise, cannabis, sexual health, plus insights on treatment.

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

Roswell Park CEO Candace S. Johnson, PhD, introduces center’s first Physician in Chief, leaders in strategic areas

A treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with TNBC.

More than a dozen teams to share advances in blood cancer treatment and research innovations at the 2024 ASH Annual Meeting.

Nurse-executive and partnership manager honored for dedication to local heroes.

Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.